<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906460</url>
  </required_header>
  <id_info>
    <org_study_id>WVE-N531-001</org_study_id>
    <nct_id>NCT04906460</nct_id>
  </id_info>
  <brief_title>Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy</brief_title>
  <official_title>An Open-label Phase 1b/2a Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wave Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wave Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2a open-label study to evaluate the safety, tolerability, pharmacokinetic&#xD;
      (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients&#xD;
      with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a&#xD;
      documented mutation of the DMD gene that is amenable to exon 53 skipping intervention&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include a total of 15 patients. An initial cohort will receive ascending doses&#xD;
      of WVE-N531. Up to 4 dose levels (administered ≥4 weeks apart) will be evaluated in order to&#xD;
      select a dose level for further multiple dose evaluation. The initial patients will receive&#xD;
      up to 3 additional doses every other week at that dose level. Additional patients will then&#xD;
      be enrolled and dosed every other week at that level. All patients will receive a maximum of&#xD;
      7 total doses followed by a minimum 8 week safety monitoring period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Proportion of patients with adverse events (AEs)</measure>
    <time_frame>Day 1 (initial dose) to a minimum of 8 weeks after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Concentration of WVE-N531 in muscle tissue</measure>
    <time_frame>Day 1 (initial dose) through 2 weeks after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531</measure>
    <time_frame>Day 1 (initial dose) through 2 weeks after the last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>WVE-N531</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WVE-N531</intervention_name>
    <description>WVE-N531 is an antisense oligonucleotide (ASO)</description>
    <arm_group_label>WVE-N531</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of DMD based on clinical phenotype with increased serum creatine kinase.&#xD;
&#xD;
          2. Documented mutation in the DMD gene associated with DMD that is amenable to exon 53&#xD;
             intervention&#xD;
&#xD;
          3. Score of ≥1 on item 1 or 2 of the shoulder component of the Performance of the Upper&#xD;
             Limb (PUL).&#xD;
&#xD;
          4. Stable pulmonary and cardiac function, as measured by the following:&#xD;
&#xD;
               1. Reproducible percent predicted forced vital capacity (FVC) ≥50%;&#xD;
&#xD;
               2. Left ventricular ejection fraction (LVEF) &gt;55% in patients &lt;10 years of age and&#xD;
                  &gt;45% in patients ≥10 years of age, as measured (and documented) by echocardiogram&#xD;
                  (ECHO) or cardiac magnetic resonance imaging (MRI), within 6 months prior to&#xD;
                  enrollment into the study.&#xD;
&#xD;
          5. Adequate deltoid muscle at Screening to perform open muscle biopsies.&#xD;
&#xD;
          6. Currently on a stable corticosteroid therapy regimen, defined as initiation of&#xD;
             systemic corticosteroid therapy that occurred ≥6 months prior to Screening and no&#xD;
             changes in dose ≤3 months prior to Screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiac insufficiency:&#xD;
&#xD;
               1. Severe cardiomyopathy that, in the opinion of the Investigator, prohibits&#xD;
                  participation in this study; however, cardiomyopathy that is managed by&#xD;
                  angiotensin-converting-enzyme (ACE) inhibitors or beta blockers is acceptable&#xD;
                  provided the participant meets the LVEF inclusion criterion.&#xD;
&#xD;
               2. Any other evidence of clinically significant structural or functional heart&#xD;
                  abnormality.&#xD;
&#xD;
               3. A cardiac troponin I value &gt;0.2 ng/mL on initial and repeat testing if initial&#xD;
                  test is elevated at Screening.&#xD;
&#xD;
          2. Need for daytime mechanical or noninvasive ventilation OR anticipated need for daytime&#xD;
             mechanical or noninvasive ventilation within the next year in the opinion of the&#xD;
             Investigator. Nighttime noninvasive ventilation is permitted.&#xD;
&#xD;
          3. Received prior treatment with an investigational peptide-conjugated phosphorodiamidate&#xD;
             morpholino oligomer (PPMO) or drisapersen.&#xD;
&#xD;
          4. Received prior treatment with gene therapy for DMD.&#xD;
&#xD;
          5. Received treatment with ataluren, viltolarsen, eteplirsen, or golodirsen within the 14&#xD;
             weeks prior to Screening.&#xD;
&#xD;
          6. Received any investigational drug within 3 months or 5 half-lives, whichever is longer&#xD;
             prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Ambulatory or non-ambulatory male</gender_description>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wave Life Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>855-215-4687</phone>
    <email>clinicaltrials@wavelifesci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Health Sciences Centre - Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig Campbell, MD MSC FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Servais, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

